Making Medicine Personal

Image: Erica P. Johnson "Never share your prescription." That's good advice: People may react differently to drugs, whether because of weight, gender, or metabolic differences. When a physician writes a prescription, one would think that it is custom-made for the patient. But, more often than not, it's "Take two and call me in the morning." Advocates of pharmacogenomics say a better approach would be to custom-design medications to fit each patient's needs; some scientists argue, however, that

Written byAileen Constans
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

"Never share your prescription." That's good advice: People may react differently to drugs, whether because of weight, gender, or metabolic differences. When a physician writes a prescription, one would think that it is custom-made for the patient. But, more often than not, it's "Take two and call me in the morning." Advocates of pharmacogenomics say a better approach would be to custom-design medications to fit each patient's needs; some scientists argue, however, that the data are simply too complex to accomplish this.

Pharmacogenomics is the study of how genetic variation influences individual responses, including metabolism and biological outcome, to a given drug or class of drugs. The field holds promise for both drug developers and patients; the latter could benefit from improved efficacy and diminished side effects. According to Rochelle Long, chief of the pharmacological and physiological sciences branch, National Institute of General Medical Sciences (NIGMS), Bethesda, Md., physicians tend ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies